Inhaled Nitric Oxide and Neuroprotection in Premature Infants (NOVA2)
Sponsor: University of Chicago
Terminated
The pace of patient enrolledment forced recruitment to stop after 273 patients.
Other terminated trials from University of Chicago
Other Bronchopulmonary Dysplasia trials with similar outcome
A PHASE2/PHASE3 clinical study on Bronchopulmonary Dysplasia and Intraventricular Hemorrhage, this trial is terminated or withdrawn. The trial is conducted by University of Chicago and has accumulated 12 data snapshots since 2008. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
12 versions recorded-
Nov 2024 — Present [monthly]
Terminated PHASE2/PHASE3
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Dec 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Oct 2019 — Dec 2020 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Nov 2018 — Oct 2019 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .